Back

The potential impact of residual inflammation and elevated Lipoprotein (a) levels in long-term cardiovascular patients' survival

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Risk factors (6) Biomarkers ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Matilde Ferreira

Hospital Funchal, Funchal (Portugal)

5 More presentations in this session

Presentation thumbnail
High-sensitivity CRP to HDL-C ratio as a novel inflammatory-lipid biomarker for mortality risk prediction: a prospective population-based cohort study
Doctor Y. Zhao (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Additional value of an integrated Polygenic Risk Score to a conventional tool in the prediction of cardiovascular events in an asymptomatic population
Doctor D. Sa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Relation of Lp(a) with plaque characteristics and clinical events: ATHEROREMO and IBIS_3 cohorts
Doctor J. Veiga-Fernandes Mira (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Circulating Lipoprotein(a) and Non-culprit Lipid-rich Plaques in Acute Coronary Syndrome and Stable Coronary Artery Disease: Findings from Near-infrared Spectroscopy Imaging Analysis
Doctor T. Iwai (Osaka, JP)
Abstract Slides Video
Presentation thumbnail
Global cardiac microcalcification activity and the risk of cardiovascular events
Doctor M. Grine (Coimbra, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors (6)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Lipoprotein(a), high-sensitive c reactive protein, and long-term survival after coronary artery bypass grafting
thumbnail
Congress Presentation
Combined effect of lipoprotein(a) and C-reactive protein on future cardiovascular outcomes after acute myocardial infarction
thumbnail
Congress Presentation
Impact of lipoprotein(a) concentrations on atherosclerotic cardiovascular disease onset: a survival analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources